| Authors: |
Furman RR; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY., Wierda WG; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Patten PEM; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital, London, United Kingdom., Chaves JM; Northwest Medical Specialties, Tacoma, WA., Brown JR; Dana-Farber Cancer Institute, Boston, MA., Munir T; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., Martin P; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY., Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Stephens DM; Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC., Ghia P; Università Vita-Salute San Raffaele, Milan, Italy.; Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy., Barrientos JC; Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY., Patel K; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., de Borja M; AstraZeneca, Mississauga, ON, Canada., Wang MH; AstraZeneca, South San Francisco, CA., Jain N; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA., Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH. |
